[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
To date, blood-pressure lowering has been the main therapeutic objective in patients with arterial hypertension, regardless of the drug used, except for drugs selected for accompanying conditions. The LIFE study, carried out in 9,193 high-risk hypertensive patients (with ECG criteria of left ventricular hypertrophy), has shown that a therapeutic regimen based on losartan combined with a thiazide was accompanied by a significant reduction in the risk of cardiovascular complications in more than 90% of patients compared with atenolol and a thiazide over a mean follow-up period of 4.8 years. The incidence of the primary endpoints (cardiovascular death, stroke, and myocardial infarction) was 11% in the losartan group and 13% in the atenolol group (13% relative risk reduction, p = 0.021). Losartan therapy was associated with more benefits in stroke risk reduction and in the development of new cases of diabetes. In the analysis of the subgroup of 1,195 patients with hypertension and diabetes included in the LIFE study, losartan had a special prognostic benefit. One of the cardiovascular events included as a primary endpoint was observed in 18% of the losartan-treated patients and in 23% of the atenolol-treated patients (24% relative risk reduction, p = 0.031). The LIFE trial showed that losartan produced better cardiovascular protection than atenolol, a similar blood pressure reduction, and was better tolerated. This drug seems to confer extra cardiovascular protection in addition to reducing blood pressure.
González-Juanatey
José R
JR
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012107:Research Design
D000959:Antihypertensive Agents; D001262:Atenolol; D019808:Losartan